Platinum Program Portfolio

Accelerating Success

Skape Bio

Skape is developing miniprotein therapeutics for integral membrane protein targets. Their platform combines de novo design with large-scale pooled screening against receptors in their native membrane environment directly in human cells.

Seen Therapeutics

Seen Therapeutics is uncovering a hidden world of tumor-specific antigens and engineering antibody-driven medicines to precisely target them. Using advanced structural and computational proteomics, Seen reveals cancer-specific features invisible to conventional discovery methods to create more selective and effective therapies.

ResNovas Therapeutics

ResNovas is a preclinical-stage biotech developing novel therapeutic approaches for highly validated but historically undruggable targets in oncology and beyond.

State 4 Therapeutics

A Yale spin-out founded in 2025 developing oral small molecule therapeutics designed to promote durable, high quality weight reduction both as single agents and in synergy with incretin therapies.

Laurel Biotherapeutics

Laurel Biotherapeutics is developing next-generation antibody therapeutics targeting pathways in cardiovascular dysfunction, inflammation, and metabolism

Overture Therapeutics

Overture Therapeutics aims to transform obesity treatment by developing precision antibody medicines that target root drivers of metabolic dysfunction and promote long-term weight loss.

Fletcher Biosciences

Fletcher Biosciences is pioneering precision biologics that selectively target the immune cells driving disease, enabling treatments with best-in-class specificity and safety.

Verto Therapeutics

Verto is developing small molecule translation inhibitors for oncology, advancing programs against Myc and other hard-to-drug targets.

Rho Bio

Rho Bio is developing therapies to restore lymphatic function. Built on discoveries from Yale and WashU, the team includes leading experts in lymphatic biology with an initial focus is on treating neuro-ophthalmic diseases caused by fluid and pressure buildup.

Deck Bio

Deck Bio is developing optimal multi-specific biologics for driving durable efficacy and safety in solid tumors using its proprietary drug discovery platform.

D2B3

Yale spinout D2B3 transiently relaxes the blood brain barrier for drug delivery to the central nervous system.

Aperture Therapeutics

Aperture Therapeutics is developing a new class of medicines mimicking protective gene variants found in resilient individuals to treat neurodegeneration. Their lead drug candidates are oligonucleotides aimed that reversing chronic neuroinflammation in ALS and FTD. The team is also building an in vitro platform to evaluate the impact of diverse human genetics on drug efficacy.

TippingPoint Biosciences

TippingPoint is a spinout from Geeta Narlikar’s lab at UCSF with a drug discovery platform that targets contextual chromatin interactions unique to disease to develop disease-selective small molecule therapeutics.

Nucyrna Therapeutics

NuCyRNA Therapeutics aims to transform RNA-targeting therapeutics by co-targeting nuclear and cytoplasmic RNAs, starting in neurodegenerative diseases.

Umlaut Bio

Umlaut is an EMBL spinout creating cancer and autoimmune therapeutics trough small molecule inhibition of tRNA modifications that globally dysregulate signaling pathway gene expression.

CloverLeaf Bio

Developing a first in class suite of engineered tRNA therapeutics for oncology, Cloverleaf is a Yale spinout aiming to inhibit tRNA modifying enzymes that are overexpressed in cancer.

Babylon Biosciences

Babylon Biosciences is a small molecule therapeutics company focused on diseases of the nervous system. The company closed an oversubscribed seed round by top tier investors in Q324 and is currently in stealth.

Velocity Bio

Velocity Bio is a Stanford University spin out accelerating allosteric drug discovery with microfluidics for difficult-to-drug enzyme targets.

Bullseye Biosciences

Bullseye Biosciences integrates AI and automation with directed evolution to unlock intracellular protein-protein interaction (PPI) therapeutics, enabling scalable drug discovery for previously undruggable targets.

Integrated Biosciences

Integrated Biosciences combines optogenetics and AI to identify new molecules targeting stress response pathways. The company closed a seed financing in H2’24.